Skip to content

Evaluating adequacy of pain relief in cancer patients attending Palliative medicine opd

Evaluation of Adequacy of Pain Relief and Medications Used in Pain Management in Cancer Patients Attending Palliative Medicine Out-Patient Department in a Tertiary Care Hospital.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/04/041806
Enrollment
400
Registered
2022-04-12
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D499- Neoplasm of unspecified behavior of unspecified site

Interventions

None listed

Sponsors

Research Society Seth GSMC KEM Hospital Mumbai
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age > 18years and willing to give consent. 2) Patients suffering from locally advanced cancer or metastatic cancer according to TNM staging II, III, and IV complaining chronic pain according to International Association for Study of Pain classification of Chronic cancer-related pain: ICD-11(REF) 3) Patients suffering from locally advanced cancer or metastatic cancer with cancer pain score 3 or more on the numerical rating scale. 4) Patients are able to give written informed consent.

Exclusion criteria

Exclusion criteria: 1) Undergone major operation within 1 month. 2) Had any interventional therapy (eg: nerve block, and neurolytic procedures) for pain.3) Patient who is currently on chemotherapy/radiotherapy or planned for chemotherapy/radiotherapy/ surgery within 7 days of starting of medication for pain. 4) Patient is disoriented, has altered sensorium, or has any psychiatric or neurological illness. 5) Patient taking more or fewer medications than the prescribed dose in subsequent followups

Design outcomes

Primary

MeasureTime frame
Adequacy of Pain relief in cancer patients attending Palliative Medicine OPDTimepoint: Pain relief is assessed at day 3 and Day 7

Secondary

MeasureTime frame
Pain Severity and Pain Interference using BPI Score and characteristics of Pain Using Mc Gill QuestionnaireTimepoint: December 2021 to November 2022

Countries

India

Contacts

Public ContactDr Harshitha Havaldar

Department of Pharmacology and Therapeutics, Seth GSMC and KEM, Mumbai

pam2671@gmail.com9619466099

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026